Get to know our clinical trials
Phase II clinical trial of disitamab vedotin in adult subjects with unresectable locally advanced or metastatic previously treated HER2-expressing solid tumors.
THE MAIN OBJECTIVE IS TO EVALUATE THE ANTITUMOR ACTIVITY OF DISITAMAB VEDOTIN IN PREVIOUSLY TREATED, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC (LA/M) HER2 EXPRESSING SOLID TUMORS.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE II BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PREVIOUSLY TREATED HER2-EXPRESSING SOLID TUMORS.
- Code EudraCT: 2023-504445-31
- Protocol number: SGNDV-005
- Promoter: Seagen Inc.
- Molecule/Drug: Disitamab Vedotin
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.